Ethan Smith, therapy area director Oncology, Norstella, explores how antibody–drug conjugates are reshaping oncology, highlighting emerging challenges around treatment sequencing, safety management ...
Antibody-drug conjugate (ADC) developers say innovations to linkers, the proteins bridging antibodies to their therapeutic payloads, are opening the door to more stable, selective ADCs with ...
LONDON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads ...
SAN FRANCISCO and SUZHOU, China, April 29, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and ...
Many of the ADC payloads have been around for decades but were previously found to be far too toxic for direct administration. For example, the payload drug SN-38 is considered to be as much as 1,000 ...
LONDON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selectively cytotoxic payloads for ...
Why Adjuvant Treatment With a CDK4/6 Inhibitor Should Be Recommended for Women With High-Risk Breast Cancer: Methodologic Considerations on Available Evidence Antibody-drug conjugates (ADCs) are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results